Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Ph not_applicable
2
50%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (33.3%)
N/A2 (66.7%)

Trials by Status

completed375%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
unknown

Establishment of a Parathyroid Tissue Bank

NCT03051126
completedphase_1

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

NCT00379080
completednot_applicable

Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury

NCT01570842
completednot_applicable

The Effects of Acute Total Sleep Deprivation Versus Normal Sleep on Metabolism

NCT01800253

Clinical Trials (4)

Showing 4 of 4 trials
NCT03051126

Establishment of a Parathyroid Tissue Bank

Unknown
NCT00379080Phase 1

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

Completed
NCT01570842Not Applicable

Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury

Completed
NCT01800253Not Applicable

The Effects of Acute Total Sleep Deprivation Versus Normal Sleep on Metabolism

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4